GlassScriptPhysician profile
Taylor Lang Kramer
NPI 1942858998
$2,495.11
in general payments reported to CMS, 2019-2025
30 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $955 · 2023: $543 · 2024: $631 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.67 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $293.14 | 2022-2025 | Lynparza, Imfinzi |
| Incyte Corporation | $250.51 | 2022 | |
| G1 Therapeutics, INC. | $217.76 | 2021-2022 | |
| Gilead Sciences, INC. | $179.91 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $165.18 | 2022-2024 | Jaypirca, Verzenio |
| Genzyme Corporation | $121.35 | 2023 | |
| Puma Biotechnology, INC. | $120.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $117.70 | 2022-2024 | Krazati, Opdualag, Augtyro |
| Janssen Scientific Affairs, LLC | $105.59 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Janssen Biotech, INC. | $97.47 | 2024 | Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $96.92 | 2023-2025 | Enhertu |
| Seagen INC. | $83.36 | 2022 | |
| Myriad Genetic Laboratories, INC. | $69.82 | 2023-2024 | Myrisk |
| Epizyme, INC. | $64.99 | 2022 | |
| Sobi, INC | $61.86 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $53.55 | 2025 | Iovera |
| Novartis Pharmaceuticals Corporation | $41.85 | 2024 | |
| Karyopharm Therapeutics INC. | $41.80 | 2022-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $38.42 | 2024 | |
| Glaxosmithkline, LLC. | $33.92 | 2022-2024 | Ojjaara |
| Pharmaessentia USA Corporation | $30.83 | 2024 | Besremi |
| Genmab U.S., INC. | $28.16 | 2024 | Epkinly |
| Geron Corporation | $26.42 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $25.85 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.97 | 2023 | Onivyde |
| Array Biopharma INC | $23.27 | 2025 | Mektovi, Tukysa, Braftovi |
| Pharmacosmos Therapeutics INC. | $22.76 | 2025 | Monoferric |
| Pfizer INC. | $22.02 | 2025 | |
| Kite Pharma, INC. | $21.21 | 2024 | Yescarta |
| Becton, Dickinson and Company | $14.69 | 2024 | Trek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.